



CIN NO.: L24230WB1982PLC034492

**Date: 29<sup>th</sup> January, 2025**

To,  
The Secretary,  
**The Calcutta Stock Exchange Limited**  
7, Lyons Range,  
Kolkata – 700 001  
Dear Sir/Madam,

**Sub: Integrated Filing (Financial) - Unaudited Financial Results of the Company for the 03<sup>rd</sup> Quarter and Nine Months ended 31.12.2024**  
**Scrip Code: 12130 (CSE)**

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31.12.2024, we are submitting herewith the Integrated Filing (Financial) – Unaudited Financial Results of the Company for the 03<sup>rd</sup> Quarter and Nine Months ended 31<sup>st</sup> December, 2024.

This information is also available on Company's website: [www.adinathbio.com](http://www.adinathbio.com) and on the Stock exchange website: [www.cse-india.com](http://www.cse-india.com).

The Company would be publishing Extract of Un-Audited Financial Result for the 03<sup>rd</sup> quarter ended 31<sup>st</sup> December, 2024, in accordance with Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015.

Request to you kindly take the above on record.

Thanking you,

Yours faithfully,

**For Adinath Bio-Labs Limited**

**SUNIL** Digitally signed  
by SUNIL KUMAR  
**KUMAR** Date: 2025.01.29  
14:51:03 +05'30'

**Sunil Kumar**  
**Managing Director & CEO**  
**DIN: 07777351**



**A. FINANCIAL RESULTS**

Statement of Standalone Unaudited Financial Results for the 3rd quarter and nine months ended 31st December, 2024							
Sl. No.	Particulars	PART I					(Rs. In Lakhs)
		Quarter Ended			Nine Months Ended		Year Ended
		Unaudited 31-12-2024	Unaudited 30-09-2024	Unaudited 31-12-2023	Unaudited 31-12-2024	Unaudited 31-12-2023	Audited 31-03-2024
<b>1</b>	<b>Income from operations</b>						
	(a) Net Sales / income from operations	-	-	-	-	-	-
	(b) Other Income	1.785	2.105	2.105	6.577	7.035	9.150
	<b>Total income from operations (net)</b>	<b>1.785</b>	<b>2.105</b>	<b>2.105</b>	<b>6.577</b>	<b>7.035</b>	<b>9.150</b>
<b>2</b>	<b>Expenses</b>						
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-	-
	(b) Employee benefits expense	1.363	1.361	1.357	4.084	4.068	5.427
	(c) Finance Cost	-	-	-	-	-	-
	(d) Depreciation and amortisation expense	-	-	-	-	-	-
	(e) Other expenses	0.769	1.339	1.209	5.170	5.365	6.852
	<b>Total expenses</b>	<b>2.132</b>	<b>2.700</b>	<b>2.566</b>	<b>9.254</b>	<b>9.433</b>	<b>12.279</b>
<b>3</b>	<b>Profit / (Loss) from operations before Exceptional &amp; Extraordinary Items (1-2)</b>	<b>(0.347)</b>	<b>(0.595)</b>	<b>(0.461)</b>	<b>(2.677)</b>	<b>(2.398)</b>	<b>(3.129)</b>
<b>4</b>	<b>Exceptional &amp; Extraordinary Items</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>(0.347)</b>	<b>(0.595)</b>	<b>(0.461)</b>	<b>(2.677)</b>	<b>(2.398)</b>	<b>(3.129)</b>
<b>6</b>	<b>Tax expense</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
	Earlier Years	-	-	-	-	-	-
	<b>Total Tax Expenses</b>	-	-	-	-	-	-
<b>7</b>	<b>Net Profit/(Loss) after tax(5 + 6)</b>	<b>(0.347)</b>	<b>(0.595)</b>	<b>(0.461)</b>	<b>(2.677)</b>	<b>(2.398)</b>	<b>(3.129)</b>
<b>8</b>	<b>Other Comprehensive Income / (Loss)</b>	-	-	-	-	-	-
<b>9</b>	<b>Total Comprehensive Income / (Loss) ( 7 ± 8 )</b>	<b>(0.347)</b>	<b>(0.595)</b>	<b>(0.461)</b>	<b>(2.677)</b>	<b>(2.398)</b>	<b>(3.129)</b>
<b>10</b>	<b>Paid-up equity share capital</b>	2,207.426	2,207.426	2,207.426	2,207.426	2,207.426	2,207.426
	(Face Value in Re.)	1	1	1	1	1	1
<b>11</b>	<b>Reserves excluding Revaluation Reserves</b>	-	-	-	-	-	(2,213.741)
<b>12</b>	<b>Earnings Per Share (not annualised except for year ended):</b>						
	Basic & Diluted	(0.000)	(0.000)	(0.000)	(0.001)	(0.001)	(0.001)

**Notes:**

- The above Unaudited Financial Results have been reviewed by the Audit Committee and adopted by the Board of Directors at their meeting held on 29th January, 2025.
- The results are based on the financial statements prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter ended and nine months ended December 31, 2024 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and issued an unqualified report in this behalf.
- Provisions for current year income tax and deferred tax will be made at the end of the year except for the earlier year which are accounted on the basis of assessment orders received by the company.
- Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

Date: 29th January, 2025.

Place: Kolkata



**By order of the Board  
For Adinath Bio-Labs Limited**

**SUNIL KUMAR**  
Digitally signed  
by SUNIL KUMAR  
Date: 2025.01.29  
14:50:42 +05'30'  
**Sunil Kumar**  
MD and CEO

DIN No.:07777351

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors  
Adinath Bio-Labs Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the quarter and nine months ended on 31<sup>st</sup> December, 2024 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KSA& Co.**  
**Chartered Accountants**  
Firm registration No: 003822C

  
**Kamal Piyush**  
Partner

Membership No: 083399  
UDIN: 25083399BM0VUX8260

Place : New Delhi  
Date : January 29, 2024

**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

<b>Statement on deviation / variation in utilisation of funds raised - Not Applicable</b>							
Name of listed entity	Not Applicable						
Mode of Fund Raising							Public Issues / Rights Issues / Preferential Issues / QIP / Others
Date of Raising Funds							
Amount Raised							
Report filed for Quarter ended							
Monitoring Agency							applicable / not applicable
Monitoring Agency Name, if applicable							
Is there a Deviation / Variation in use of funds raised							Yes / No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders							
If Yes, Date of shareholder Approval							
Explanation for the Deviation / Variation	Not Applicable						
Comments of the Audit Committee after review							
Comments of the auditors, if any							
Objects for which funds have been raised and where there has been a deviation, in the following table							
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any	
<p><b>Deviation or variation could mean:</b></p> <p>(a) Deviation in the objects or purposes for which the funds have been raised or</p> <p>(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or</p> <p>(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.</p> <p><b>Sunil Kumar</b> Managing Director and CEO DIN: 07777351</p>							

SUNIL KUMAR  
Digitally signed by SUNIL KUMAR  
Date: 2025.01.29 14:50:20 +05'30'



**C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES**

S. No.	Particulars	in INR crore
<b>1.</b>	<b>Loans / revolving facilities like cash credit from banks / financial institutions</b>	
A	Total amount outstanding as on date	NIL
B	Of the total amount outstanding, amount of default as on date	NIL
<b>2.</b>	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	
A	Total amount outstanding as on date	NIL
B	Of the total amount outstanding, amount of default as on date	NIL
<b>3.</b>	<b>Total financial indebtedness of the listed entity including short-term</b>	<b>NIL</b>

**D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4<sup>th</sup> quarter) – Not Applicable.**

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – Not Applicable.**

For Adinath Bio-Labs Limit

**SUNIL** Digitally signed  
by SUNIL KUMAR  
Date: 2025.01.29  
**KUMAR** 14:50:03 +05'30'

**Sunil Kumar**  
**Managing Director & CEO**  
**DIN: 07777351**

